P
P

Pfizer


Balita

New York Times business news - Sept 24

Sept 24 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - The director of the Centers for Disease Control and Prevention on Friday overruled a recommendation by an agency advisory panel that had refused to endorse booster shots of the P
P

Australia shares slip as gold, metal stocks drag

Sept 24 (Reuters) - Australian shares fell on Friday, dragged by heavyweight gold and metal stocks on weaker bullion and copper prices overnight, while gains in energy stocks and banks limited the losses. The benchmark S&P/ASX 200 index .AXJO fell 0.21% to 7,354.9 points as at 0137 GMT and headed for its third weekly loss. Gold prices fell about 1%
A
N
P
Q
W
B
J

New York Times business news - Sept 23

Sept 23 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - After weeks of internal strife at the U.S. Food and Drug Administration, the agency on Wednesday authorized people over 65 who had received Pfizer-BioNTech's COVID-19 vaccine to
A
P

Wall Street Journal - Sept 23

Sept 23 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - U.S. health authorities cleared COVID-19 vaccine booster shots for people 65 and older and certain other adults at high risk of severe illness, a bid to help curb the pandemic and the dang
A
F
P
U

Canada - Sept. 21

Sept 21 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy. THE GLOBE AND MAIL ** Bank of Montreal Wealth Management head Joanna Rotenberg will replace Kathy Murphy as the head of Fidelity's US$4.1-trillion personal investing division at the e
P

Wall Street Journal - Sept 21

Sept 21 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Coinbase Global Inc COIN.O won't offer a lending program that drew the threat of enforcement action from U.S. regulators. Link - Pfizer Inc PFE.N and partner BioNTech SE 22UAy.DE said thei
P

Regulators could OK Pfizer boosters for older Americans this week

By Michael Erman Sept 20 (Reuters) - U.S. regulators could authorize a booster shot of the Pfizer Inc PFE.N /BioNTech SE BNTX.O COVID-19 vaccine for older and some high-risk Americans early this week in time for the government to roll them out by Friday. The Food and Drug Administration is expected to give the nod to the third shots for at least th
P

Pfizer/BioNTech say data show 19 vaccine safe and protective in kids

By Michael Erman Sept 20 (Reuters) - Pfizer Inc PFE.N and BioNTech SE BNTX.O said on Monday their COVID-19 vaccine induced a robust immune response in 5 to 11 year olds, and they plan to ask for regulatory authorization as soon as possible to use the shot in children in that age range in the United States, Europe and elsewhere. The companies said t
P

Thailand to try alternative 19 vaccination method to stretch supplies

By Panarat Thepgumpanat and Chayut Setboonsarng BANGKOK, Sept 20 (Reuters) - Doctors in Thailand have been given the go-ahead to start giving COVID-19 booster shots under the skin, rather than injecting them into muscles, officials said on Monday, in an effort to strengthen immunity and stretch vaccine supplies. Health Minister Anutin Charnvirakul
A
P

Pfizer/BioNTech say data show 19 vaccine safe and protective in kids

By Michael Erman Sept 20 (Reuters) - Pfizer Inc PFE.N and BioNTech SE BNTX.O said on Monday their COVID-19 vaccine induced a robust immune response in 5 to 11 year olds, and they plan to ask for authorization to use the vaccine in children in that age range in the United States, Europe and elsewhere as soon as possible. The companies said the vacci
P

Regulators expected to OK Pfizer boosters for older Americans this week

By Michael Erman Sept 20 (Reuters) - U.S. regulators are expected to authorize a third booster shot of the Pfizer Inc PFE.N /BioNTech SE BNTX.O COVID-19 vaccine for older and some high-risk Americans early this week in time for the government to roll them out by Friday as hoped. The Food and Drug Administration is expected to give the nod to the sh
P

Here's what you need to know about the coronavirus right now

Sept 20 (Reuters) - Here's what you need to know about the coronavirus right now: Pfizer, BioNTech say data show vaccine safe in kids Pfizer and BioNTech said on Monday their COVID-19 vaccine induced a robust immune response in 5-to-11 year-olds, and they plan to seek authorisation to use the vaccine in children in that age range in Europe, the Uni
P

Wall Street closes rollercoaster week sharply lower

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.) * Nasdaq leads losses as technology majors sink * S&P 500 ends below 50-day moving average * Triple options expiry causes late session volume spike * Indexes post weekly losses * Indexes down: Dow 0.48%, S&P 0.91%, Nasdaq 0.91% (Updates with closing prices) By Stephen
P
U
U

Wall Street ends rollercoaster week sharply lower

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.) (Updates to market close) By Stephen Culp NEW YORK, Sept 17 (Reuters) - U.S. stocks closed sharply lower in a broad sell-off on Friday, ending a week buffeted by strong economic data, corporate tax hike worries, the Delta COVID variant, and possible shifts in the U.S.
P
U
U

Wall Street slides, ending seesaw week in a risk-off mood

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.) * Nasdaq leads losses as technology majors sink * S&P 500 trades close to 50-day moving average * Triple options expiry likely to increase volatility * Indexes set for weekly losses * Indexes down: Dow 0.49%, S&P 0.87%, Nasdaq 1.05% By Stephen Culp NEW YORK, Sept 17 (
P
U
U

Sri Lankan shares log second straight weekly loss; nationwide curfew extended

Sept 17 (Reuters) - Sri Lankan shares clocked their second consecutive weekly loss as the island nation further extended its lockdown until Oct. 1 to tackle an upsurge in coronavirus cases. * The country's President Gotabaya Rajapaksa on Friday advised the health sector to administer Pfizer Inc's PFE.N COVID-19 vaccine to children between the ages
P

Hong Kong panel advises single dose of BioNTech COVID shot for teens

By Farah Master HONG KONG, Sept 16 (Reuters) - A panel of health experts advising the Hong Kong government has recommended children aged 12-17 should get only one dose of BioNTech's 22UAy.DE COVID-19 vaccine after reports of heart inflammation as a side effect. Professor Lau Yu-lung, who chairs the health committee advising the government on its va
P

New York Times business news - Sept 16

Sept 16 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - The Food and Drug Administration offered the first public look at Pfizer Inc's PFE.N application for a booster coronavirus shot, two days before an outside advisory committee of
P

Hong Kong panel recommends single dose of BioNTech's 19 shot for teenagers

HONG KONG, Sept 16 (Reuters) - A panel of health experts advising the Hong Kong government has recommended children aged 12-17 should get only one dose of BioNTech's 22UAy.DE COVID-19 vaccine after reports of heart inflammation side effects. Professor Lau Yu-lung, who chairs a health committee advising the government on its vaccination programme, t
P

UK plans COVID boosters for over 50s to cope with "bumpy" winter

* Booster shot recommended for all Britons over 50 * Third shot also eyed for vulnerable and some health staff * Johnson hopes "Plan B" can avoid economically damaging lockdowns * Winter could be bumpy at times, health official says By Alistair Smout LONDON, Sept 14 (Reuters) - Britain will begin a COVID-19 vaccine booster programme for older and m
P



Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Ang iyong kapital ay maaaring malugi. Ang mga produktong naka-leverage ay maaaring hindi para sa lahat. Tingnan ang aming Risk Disclosure.